Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a distinct form of pulmonary hypertension. PH in ILD drives a greater degree of functional impairment, healthcare utilization, and mortality than does underlying lung disease alone. A lack of PH-ILD-specific pharmacologic options had historically led to off-label use of medications for this condition, despite a paucity of evidence supporting their use in this patient population. The first FDA approval of a PH-ILD therapy gives prescribers the ability to move towards a more uniform evidence-based treatment approach. This CME-accredited publication in the Journal of Managed Care and Specialty Pharmacy (JMCP) will discuss: definition, scope, and burden of PH-ILD complex pathophysiology diagnostic challenges data for therapies that have been used off-label in PH-ILD patients pharmacologic advances and the resulting implications for managed care latest guidelines.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/print/aligning-payer-decision-making-latest-advances-diagnosis-treatment-ph-ild
- Start Date: 2025-01-01 06:00:00
- End Date: 2025-01-01 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: United Therapeutics - Amount: 65000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all